Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcripts
Trevi Therapeutics, Inc.'s Latest Earnings Call - May 13, 2026
Trevi Therapeutics reported its Q1 2026 earnings, focusing on its single asset, nalbuphine ER, targeting chronic cough conditions. Management highlighted a potential $6 billion peak sales opportunity, driven by positive data in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough. The company has $300 million in cash, sufficient to fund operations through 2030. No revenue or earnings figures were disclosed, and no changes to guidance were mentioned.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $300 million (inline) |
| Peak Sales Opportunity | $6 billion (positive) |
| Phase IIb Study Completion | 160 patients (positive) |
| Adverse Event Rate | 5% to 5.5% (inline) |
Guidance from management
Management did not provide specific forward guidance figures but indicated that ongoing trials are on track, with results expected in 2027 and 2028.
What analysts pressed on
Analysts questioned the potential market penetration given the competitive landscape and the need for further validation of nalbuphine ER's efficacy in larger trials. Concerns also included the timeline for commercialization and potential funding needs for Phase III trials.
Main topics on the call
- Nalbuphine ER Efficacy — Trevi's nalbuphine ER showed positive data in both IPF and refractory chronic cough. Management emphasized its unique mechanism, stating, 'We are the only investigational therapy that's had positive data in both idiopath...
- Market Opportunity — Management highlighted a $6 billion-plus peak sales opportunity for nalbuphine ER, driven by its efficacy in treating chronic cough conditions. They plan to market the drug independently, leveraging a specialty sales mod...
- Clinical Trial Progress — Trevi is advancing two studies, OCEAN 1 and OCEAN 2, with readouts expected in 2027 and 2028. The studies aim to confirm nalbuphine ER's efficacy and safety over 52 and 12 weeks, respectively.
- Adverse Events — Adverse events were mostly mild to moderate, with similar discontinuation rates between placebo and drug arms. '95% of these adverse events were mild to moderate,' noted management.
Read the full Trevi Therapeutics, Inc. transcript (May 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 34 calls on record spanning August 13, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 34 Trevi Therapeutics, Inc. earnings call transcripts on record, spanning August 13, 2020 to August 6, 2026. Based on this history, Trevi Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- TRVI
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 34
- First call
- August 13, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly